Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.
Day Range1.250 - 1.420 | 52 Wk Range0 - 3.630 | Open / Close1.310 / - | Float / Outstanding- / 22.594M |
Vol / Avg.40.027K / 1.446M | Mkt Cap30.581M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.300 |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-04-09 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Comera Life Sciences (NASDAQ:CMRA), Lumos Pharma (NASDAQ:LUMO) and Harpoon Therapeutics (NASDAQ:HARP).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.